InnoCan Pharma (INNPF) Stock Statistics & Valuation Metrics

InnoCan Pharma has a market cap or net worth of $44.78M. The enterprise value is $39.72M.

InnoCan Pharma has 292,420,170 shares outstanding. The number of shares has decreased by -2.65% in one year.

InnoCan Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is 5.06%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, InnoCan Pharma had revenue of 29.44M and earned -1.83M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -464.00K and capital expenditures -18.00K, giving a free cash flow of -482.00K billion.

InnoCan Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

InnoCan Pharma upcoming earnings date is ―, ―.

InnoCan Pharma as a current ratio of 4.09, with Debt / Equity ratio of 27.82%

In the past 12 months, InnoCan Pharma has paid 1.18M in taxes.

InnoCan Pharma EV to EBITDA ratio is 37.32, with an EV/FCF ratio of -22.50.

InnoCan Pharma has $6.37M in cash and marketable securities with $1.30M in debt, giving a net cash position of -$5.06M billion.

Gross margin is 89.61%, with operating margin of -4.24%, and net profit margin of -6.23%.

The average price target for InnoCan Pharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold